Type 1 & Type 2
Diabetes
Quantifying active beta-cell biology to guide diagnosis, monitoring, and therapeutic response.
The First Molecular Platform Built for Disease Interception.
Kihealth Labs is developing next-generation molecular diagnostics that detect disease at its earliest biological stages through proprietary liquid biopsy technology, advanced biomarker science, and AI-powered clinical intelligence.
Trust & Recognition
2025
ADA Innovation of the Year
Collaborators
Academic
Institutions
Research
Partners
Clinical
Portfolio
Patent
Research
Peer-Reviewed
The Problem We Exist to Solve
The Earlier We Detect Disease, the More Lives We Can Change.
Diabetes and metabolic disease often develop silently for years before symptoms appear. By the time conventional diagnostic tests identify disease, irreversible cellular damage may already have occurred. Kihealth Labs is developing molecular diagnostics designed to detect disease earlier — when intervention has the greatest potential to improve outcomes.
A Global Health Crisis Demands Earlier Detection
Diabetes and metabolic disease have become one of the greatest healthcare challenges of our time. Disease often progresses silently for years before traditional clinical tests identify a problem. Kihealth is developing molecular diagnostics designed to detect disease earlier — when intervention has the greatest opportunity to improve long-term outcomes.
537M
Adults living with diabetes worldwide
A global health crisis affecting every region and population.
783M
Projected to have diabetes by 2045
Without earlier detection, prevalence will continue to rise sharply.
$1T+
Spent globally each year on diabetes care
The economic weight of late-stage disease continues to climb.
1B+
People living with obesity worldwide
A leading driver of metabolic dysfunction and cardiometabolic disease.
96M
Americans have prediabetes — most unaware
Silent progression continues for years without clinical signs.
Up to 90%
Of Type 2 diabetes may be preventable
Earlier intervention and lifestyle modification can change trajectories.
Years
Before symptoms appear
Beta-cell dysfunction and molecular changes begin long before diagnosis.
National Recognition
Recognized as the American Diabetes Association's 2025 Innovation of the Year
Kihealth was honored with the Innovation of the Year Award at the 2025 American Diabetes Association Scientific Sessions, recognizing our pioneering work in developing next-generation blood-based diagnostics for the earliest detection of metabolic disease. This award reflects the scientific innovation, clinical potential, and transformative impact of the InterceptIQ™ platform and reinforces Kihealth's position as a leader in precision, preventative medicine.
Our Identity
Who We Are
Building the next generation of molecular diagnostics to detect disease before symptoms appear.
KiHealth Labs is a molecular diagnostics company developing advanced blood-based technologies designed to identify disease at its earliest biological stages.
Our proprietary Intercept IQ™ Platform combines multi-omic biomarker discovery, molecular diagnostics, artificial intelligence, clinical research, and longitudinal data to create scalable diagnostic solutions across multiple disease areas.
Rather than waiting for disease to become clinically apparent, our mission is to enable earlier detection, earlier intervention, and better patient outcomes.
Molecular Diagnostics
Developing highly sensitive blood-based molecular diagnostics capable of identifying biological changes before conventional clinical testing.
Intercept IQ™ Platform
A proprietary multi-omic platform integrating biomarker discovery, laboratory science, artificial intelligence, and longitudinal clinical evidence.
Clinical Research
Generating robust analytical and clinical validation through academic collaborations, prospective studies, and translational medicine.
Artificial Intelligence & Data Science
Transforming molecular biology and real-world clinical data into predictive models that improve diagnostic performance and clinical decision-making.
Precision Medicine
Supporting personalized healthcare through earlier detection, individualized risk assessment, and disease-specific molecular insights.
Multi-Disease Innovation
Building a scalable diagnostic platform with applications across diabetes, metabolic disease, oncology, neurodegeneration, and future disease programs.
The Problem
The Metabolic Disease Crisis
Metabolic disease is one of the largest and fastest-growing healthcare challenges in the world, yet most patients are identified only after significant biological damage has already occurred.
- Stage 01
Healthy Metabolism
Insulin signaling intact · glucose tightly regulated
—Baseline biology
- Stage 02
Insulin Resistance
Cells become less responsive · beta cells compensate
~1 in 3U.S. adults with prediabetes (CDC)
- Stage 03
Beta Cell Stress
Chronic overproduction strains pancreatic islet cells
~80%of prediabetes is undiagnosed (CDC)
- Stage 04
Beta Cell Death
Cellular apoptosis begins · function silently erodes
Yearsof damage before clinical detection
- Stage 05
Prediabetes
Glucose dysregulation emerges · still reversible
537Mpeople living with diabetes globally (IDF)
- Stage 06
Type 2 Diabetes
Clinical thresholds crossed · diagnosis confirmed
~240Mpeople living with undiagnosed diabetes (IDF)
- Stage 07
Complications
Cardiovascular, renal, neurological, retinal injury
$1T+estimated annual global cost of diabetes
What if we could evaluate disease biology earlier?
The Biological Progression
Where disease begins — and where Kihealth intercepts.
The Kihealth Window
1–5 years before symptoms
Molecular biomarkers reveal disease biology while it is still actionable — long before clinical symptoms appear.
- Stage 01Healthy Biology
- Stage 02Cellular Stress
- Stage 03Beta Cell Injury
- Stage 04Molecular Biomarkers
- Stage 05Clinical Symptoms
- Stage 06Traditional Diagnosis
Kihealth detection window
Conventional diagnostics
The Science of Earlier Detection
The Window of Opportunity for Early Intervention
Beta-cell death increases first. Functional beta-cell mass remains preserved. HbA1c stays normal. This creates a unique window where Kihealth enables earlier detection and intervention — before irreversible loss occurs.
HbA1c
Late Marker of Glycemic Dysfunction
Stable early, rising sharply only once significant beta-cell loss has occurred.
Functional Beta-Cell Mass
Insulin-Producing Capacity
Largely preserved through the window of opportunity, then declines once clinical dysfunction begins.
% Demethylated INS cfDNA
Direct Measurement of Beta-Cell Death
Rises first — peaking inside the window — then declines as the at-risk reserve is depleted.
Traditional Biomarkers Remain Stable
HbA1c and glucose often stay within the normal range while silent beta-cell injury is already underway.
Kihealth Detects Active Beta-Cell Death
Demethylated INS cfDNA rises as beta cells undergo apoptosis — a direct, earlier molecular signal.
Intervene Before Irreversible Loss
Earlier detection opens the window to preserve functional beta-cell mass before substantial loss has occurred.
The Biology
At the center of metabolic disease — the beta cell.
The health of a single cell type — the pancreatic beta cell — defines whether a patient stays metabolically well, or doesn't.
The Intercept IQ™ Platform
A next-generation multi-omic diagnostic platform integrating molecular biology, advanced laboratory technologies, artificial intelligence, and longitudinal clinical data — to detect disease earlier and enable precision medicine across multiple disease areas.
Intercept IQ™ is the scientific engine behind every Kihealth diagnostic program. Rather than relying on a single biomarker, the platform integrates multiple biological signals, advanced molecular technologies, and continuously expanding clinical datasets to identify disease at its earliest biological stages.
01 · Architecture
A connected ecosystem of biological intelligence.
Every technology pillar feeds a shared molecular intelligence layer — biological signals flow inward, and validated diagnostic insight flows outward across every Kihealth disease program.
Multi-Omic Biomarker Discovery
Integrated signal across genomics, epigenomics, and proteomics to reveal early disease biology.
Cell-Free DNA Analysis
Ultra-sensitive detection of circulating molecular fragments released by stressed and damaged tissues.
Epigenetic Biomarkers
Methylation and chromatin signatures that capture disease state before genetic mutation.
Gene Sequencing
Targeted and whole-genome sequencing to resolve variant biology at clinical grade.
Digital PCR & Proteomics
Absolute quantification of low-abundance nucleic acid and protein biomarkers.
AI & Machine Learning
Models trained on multi-modal biological signal to translate complexity into clinical risk.
Longitudinal Clinical Data
Multi-year outcomes linked to molecular readouts across diverse patient populations.
Predictive Disease Modeling
Real-world evidence fused with molecular biology to forecast disease trajectory.
Multi-Omic Biomarker Discovery
Integrated signal across genomics, epigenomics, and proteomics to reveal early disease biology.
Cell-Free DNA Analysis
Ultra-sensitive detection of circulating molecular fragments released by stressed and damaged tissues.
Epigenetic Biomarkers
Methylation and chromatin signatures that capture disease state before genetic mutation.
Gene Sequencing
Targeted and whole-genome sequencing to resolve variant biology at clinical grade.
Digital PCR & Proteomics
Absolute quantification of low-abundance nucleic acid and protein biomarkers.
AI & Machine Learning
Models trained on multi-modal biological signal to translate complexity into clinical risk.
Longitudinal Clinical Data
Multi-year outcomes linked to molecular readouts across diverse patient populations.
Predictive Disease Modeling
Real-world evidence fused with molecular biology to forecast disease trajectory.
02 · How It Works
From molecular discovery to clinical deployment.
01
Discover
Identify novel molecular biomarkers associated with the earliest biological changes in disease.
02
Validate
Generate analytical and clinical evidence through laboratory validation and prospective clinical research.
03
Predict
Integrate AI, machine learning, and longitudinal datasets to improve disease risk assessment and clinical decision support.
04
Scale
Deploy validated molecular diagnostics across multiple disease indications while continuously strengthening the platform with new insights.
03 · Core Technologies
A stack engineered for early biological signal.
Fourteen integrated technology domains — spanning wet-lab, molecular, computational, and clinical data science — combined into a single interception platform.
Multi-Omics
Cell-Free DNA
Epigenetics
Transcriptomics
Proteomics
Gene Sequencing
Digital PCR
Molecular Biology
Bioinformatics
Artificial Intelligence
Machine Learning
Predictive Analytics
Clinical Data Integration
Real-World Evidence
04 · What Makes It Different
Why Intercept IQ™ is different
Built for interception. Designed to compound.
Intercept IQ™ is architected around one principle: the earlier disease biology can be seen, the more medicine can do. Every layer of the platform — biological, data, and clinical — is designed to strengthen with every new study and every new patient.
Interception, not confirmation
Engineered to detect disease biology at its earliest actionable stage — years before conventional diagnosis.
Multi-layer biological signal
Fuses genomic, epigenomic, proteomic, and cell-free signals instead of relying on any single biomarker.
Continuously learning
Every clinical study, dataset, and real-world outcome strengthens the models and expands biological insight.
Scalable across disease areas
One platform architecture spanning diabetes, metabolic disease, oncology, neurodegeneration, and beyond.
Disease Programs
Where our platform is being applied.
Kihealth Labs is advancing molecular diagnostics across a portfolio of diseases where earlier detection can meaningfully change patient outcomes.
Early Intervention
Prediabetes
Detecting metabolic dysfunction years before conventional markers become abnormal.
MASH & Beyond
Metabolic Disease
Molecular readouts of hepatic and systemic metabolic injury for earlier clinical action.
Early Detection Research
Pancreatic Cancer
Investigating tissue-of-origin signals to surface pancreatic malignancy at treatable stages.
Exploratory Program
Neurodegenerative Disease
Extending the platform to neurologic tissue signals for pre-symptomatic detection.
The Technology
A blood draw, decoded.
Six tightly-coupled stages turn a single tube of plasma into a quantitative readout of active beta-cell biology.
The InterceptIQ pipeline is a continuous instrument loop. Every stage is quality-controlled, traceable, and engineered to preserve fragmentomic detail from picogram-level input through clinical reporting.
Applications
One platform.
Many applications.
InterceptIQ™ generates biological intelligence across prevention, clinical care, therapeutic innovation, and population health.
Population Screening
Identify metabolic risk earlier across communities and systems.
EXPLORE
Clinical Trials
Stratify and monitor patient populations for therapeutic development.
EXPLORE
GLP-1 Monitoring
Quantify biological response to GLP-1 and metabolic therapies.
EXPLORE
Functional & Longevity
Evaluate metabolic health through a root-cause clinical lens.
EXPLORE
Pediatric Diabetes
Support pediatric Type 1 diabetes screening and monitoring.
EXPLORE
Employer Programs
Power workforce health and preventative initiatives at scale.
EXPLORE
Clinical Validation
Built on academic rigor.
Multi-center cohorts, leading institutions, and a growing body of peer-reviewed evidence — the foundation beneath every result Kihealth returns.
View the full validation dashboard10+
Academic partners
7+
Clinical sites
1,200+
Patient samples
4
Publications & posters
Academic & Clinical Partners
A trusted network of leading institutions.
Multi-center collaborations with the academic and clinical organizations defining the future of metabolic health.
Credibility
From Yale discovery to global platform.
Kihealth's science traces directly to foundational Type 1 diabetes research at Yale — translated, protected, and engineered into a commercial diagnostics platform.
- YaleFoundational researchBeta cell cfDNA biology — Herold Lab
- DiscoveryScientific platformMethylation atlas validated
- IPPatent protection7+ patent assets secured
- ClinicalMulti-center validationTEDDY · DAISY · Nemours · UF
- TodayCommercial platformInterceptIQ™ in market
- GlobalExpansionPartnerships & programs worldwide
The Future
Disease interception, years earlier.
Partner with Kihealth to bring metabolic intelligence to clinicians, pharmaceutical programs, and the patients waiting on better answers.